全文获取类型
收费全文 | 8030篇 |
免费 | 645篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 193篇 |
妇产科学 | 133篇 |
基础医学 | 870篇 |
口腔科学 | 200篇 |
临床医学 | 765篇 |
内科学 | 2029篇 |
皮肤病学 | 189篇 |
神经病学 | 785篇 |
特种医学 | 414篇 |
外科学 | 1078篇 |
综合类 | 250篇 |
一般理论 | 28篇 |
预防医学 | 657篇 |
眼科学 | 275篇 |
药学 | 476篇 |
1篇 | |
中国医学 | 16篇 |
肿瘤学 | 322篇 |
出版年
2023年 | 56篇 |
2021年 | 93篇 |
2020年 | 93篇 |
2019年 | 151篇 |
2018年 | 177篇 |
2017年 | 148篇 |
2016年 | 118篇 |
2015年 | 129篇 |
2014年 | 173篇 |
2013年 | 288篇 |
2012年 | 377篇 |
2011年 | 424篇 |
2010年 | 262篇 |
2009年 | 222篇 |
2008年 | 385篇 |
2007年 | 397篇 |
2006年 | 407篇 |
2005年 | 362篇 |
2004年 | 306篇 |
2003年 | 335篇 |
2002年 | 250篇 |
2001年 | 187篇 |
2000年 | 191篇 |
1999年 | 184篇 |
1998年 | 99篇 |
1997年 | 87篇 |
1996年 | 86篇 |
1995年 | 92篇 |
1994年 | 81篇 |
1993年 | 69篇 |
1992年 | 168篇 |
1991年 | 142篇 |
1990年 | 131篇 |
1989年 | 153篇 |
1988年 | 148篇 |
1987年 | 153篇 |
1986年 | 148篇 |
1985年 | 133篇 |
1984年 | 108篇 |
1983年 | 66篇 |
1982年 | 61篇 |
1979年 | 90篇 |
1978年 | 82篇 |
1977年 | 67篇 |
1976年 | 58篇 |
1975年 | 55篇 |
1974年 | 69篇 |
1973年 | 61篇 |
1972年 | 62篇 |
1971年 | 59篇 |
排序方式: 共有8717条查询结果,搜索用时 31 毫秒
1.
Marita Zimmermann Solomon J. Lubinga Reiner Banken David Rind Geri Cramer Patricia G. Synnott Richard H. Chapman Sonya Khan Josh Carlson 《Value in health》2019,22(2):161-167
Objective
The gene therapy voretigene neparvovec (VN) is the first Food and Drug Administration–approved treatment for vision loss owing to the ultra-rare RPE65-mediated inherited retinal disorders. We modeled the cost-utility of VN compared with standard of care (SoC).Study Design
A 2-state Markov model, alive and dead, with a lifetime horizon.Methods
Visual acuity (VA) and visual field (VF) were tracked to model quality-adjusted life-years (QALYs). VN led to an improvement in VA and VF that we assumed was maintained for 10 years followed by a 10-year waning period. The cost of VN was $850 000, and other direct medical costs for depression and trauma were included for a US healthcare system perspective. A modified societal perspective also included direct nonmedical costs and indirect costs.Results
VN provided an additional 1.3 QALYs over the remaining lifetime of an individual. The average total lifetime direct medical cost for individuals treated with VN was $1 039 000 compared with $213 400 for SoC, leading to an incremental cost-effectiveness ratio (ICER) of $643 800/QALY from the US healthcare system perspective. Direct nonmedical costs totalled $1 070 900 for VN and $1 203 300 for SoC, and indirect costs totalled $405 400 for VN and $482 900 for SoC, leading to an ICER of $480 100/QALY from the modified societal perspective.Conclusions
At the current price, VN was unlikely to reach traditional cost-effectiveness standards compared with SoC. VN has important implications for both development and pricing of future gene therapies; therefore clinical and economic analyses must be carefully considered. 相似文献2.
Here at the Center, we had the privilege of seeing how Dan Callahan lived out his last days and weeks. True to his nature, Dan never stopped thinking or writing. Indeed, his wife Sidney told me that he finished his last essay one day before his death, on July 16th, insisting that she help him get to the computer so he could discuss it with a colleague. “It's my last one,” he told her with his characteristic self‐awareness. Dan also chose the last topic he would focus on: climate change. At a December 2018 board meeting, Dan presented his desire to develop a workshop to explore the ways in which bioethics in general, and The Hastings Center in particular, might be able to make a valuable contribution to addressing the problem of global warming. 相似文献
3.
Alexandre Hideo-Kajita Toby Rogers Kyle Buchanan Micaela Iantorno Deepakraj Gajanana Yuichi Ozaki Kazuhiro Dan Paul Kolm Echo Brathwaite Solomon Beyene Gebremedhin Melaku Yael Meirovich Aaphtaab Dheendsa Hector M. Garcia-Garcia Rebecca Torguson Ron Waksman 《The American journal of cardiology》2019,123(8):1228-1238
4.
5.
Candice L. Swift Katherine B. Louie Benjamin P. Bowen Heather M. Olson Samuel O. Purvine Asaf Salamov Stephen J. Mondo Kevin V. Solomon Aaron T. Wright Trent R. Northen Igor V. Grigoriev Nancy P. Keller Michelle A. OMalley 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(18)
6.
Latika Nagpal Michael D. Kornberg Lauren K. Albacarys Solomon H. Snyder 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(6)
Inositol hexakisphosphate kinases (IP6Ks) regulate various biological processes. IP6Ks convert IP6 to pyrophosphates such as diphosphoinositol pentakisphosphate (IP7) and bis-diphosphoinositol tetrakisphosphate (IP8). IP7 is produced in mammals by a family of inositol hexakisphosphate kinases, IP6K1, IP6K2, and IP6K3, which have distinct biological functions. The inositol hexakisphosphate kinase 2 (IP6K2) controls cellular apoptosis. To explore roles for IP6K2 in brain function, we elucidated its protein interactome in mouse brain revealing a robust association of IP6K2 with creatine kinase-B (CK-B), a key enzyme in energy homeostasis. Cerebella of IP6K2-deleted mice (IP6K2-knockout [KO]) produced less phosphocreatine and ATP and generated higher levels of reactive oxygen species and protein oxidative damage. In IP6K2-KO mice, mitochondrial dysfunction was associated with impaired expression of the cytochrome-c1 subunit of complex III of the electron transport chain. We reversed some of these effects by combined treatment with N-acetylcysteine and phosphocreatine. These findings establish a role for IP6K2–CK-B interaction in energy homeostasis associated with neuroprotection.Inositol pyrophosphates are versatile messenger molecules that mediate a variety of cellular functions, including cell growth, apoptosis, endocytosis, and cell differentiation. The most extensively studied inositol pyrophosphate, diphosphoinositol pentakisphosphate (IP7), displays a 5′-diphosphate (1, 2). IP7 is generated in mammals by a family of inositol hexakisphosphate kinases (IP6Ks) (3, 4). IP6Ks exists in three isoforms: IP6K1, IP6K2, and IP6K3. Inositol hexakisphosphate kinase-2 (IP6K2) sensitizes cells to apoptosis (5, 6). Mice with targeted deletion of IP6K2 display an increased incidence of aero-digestive tract carcinoma (7). Cell survival associated with heat shock protein 90 also involves IP6K2 (8, 9).We previously reported a major role for IP6K2 in the disposition of cerebellar granule cells as well as Purkinje cell morphology and motor coordination. The influence of IP6K2 upon cerebellar disposition involved protein 4.1N, both of which were highly expressed in cerebellar granule cells (10).To further assess the functions of IP6K2 in the brain, we explored its binding partners using coimmunoprecipitation and tandem liquid chromatography mass spectrometry (LC-MS/MS). Here, we report that IP6K2 robustly interacts with creatine kinase-B (CK-B), which regulates energy homeostasis of cells and exists in two forms, brain type (CK-B) and muscle type (CK-M). CK catalyzes the reversible transfer of the phosphate group of phosphocreatine to ADP to yield ATP (11, 12). A functional interplay between mitochondrial and cytosolic isoforms of CK regulates cellular energy homeostasis. Cytosolic CK rephosphorylates locally produced free ADP and increases creatine globally, while the mitochondrial enzyme catalyzes the conversion of creatine to phosphocreatine utilizing mitochondrial ATP (13–15).Here, we show that IP6K2 loss leads to decreased CK-B expression, reduced ATP levels, and diminished mitochondrial activity associated with increased oxidative stress. About 80 to 90% of ATP is generated in the mitochondria by oxidative phosphorylation, and diminished ATP levels are the immediate effect of mitochondrial dysfunction. Loss of IP6K2 and CK-B reflects the suppression of the mitochondrial cytochrome c1 expression, a component of complex III of the mitochondrial electron transport chain. In the present study, we report a physiologic association of CK-B and IP6K2, whose disruption impacts mitochondrial functions.Dendritic morphogenesis was reduced in IP6K2-deficient neurons and was rescued by restoring normal levels of ATP. These observations reveal an essential role of IP6K2 in the energy production of the brain. Our findings indicate that IP6K2 is a key regulator of mitochondrial homeostasis which promotes neuroprotection. 相似文献
7.
8.
Fabian M. Laage Gaupp Nadia Solomon Ivan Rukundo Azza A. Naif Erick M. Mbuguje Anish Gonchigar Minzhi Xing John D. Prologo Douglas D. Silin Frank J. Minja 《Journal of vascular and interventional radiology : JVIR》2019,30(12):2036-2040
Despite a population of nearly 60 million, there is currently not a single interventional radiologist in Tanzania. Based on an Interventional Radiology (IR) Readiness Assessment, the key obstacles to establishing IR in Tanzania are the lack of training opportunities and limited availability of disposable equipment. An IR training program was designed and initiated, which relies on US-based volunteer teams of IR physicians, nurses, and technologists to locally train radiology residents, nurses, and technologists. Preliminary results support this strategy for addressing the lack of training opportunities and provide a model for introducing IR to other resource-limited settings. 相似文献
9.
10.